Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2006-05-02
2006-05-02
Smith, Lynette R. F. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S184100, C424S236100, C424S246100, C530S350000, C435S221000
Reexamination Certificate
active
07037503
ABSTRACT:
The invention provides mutant forms of pore-forming toxins. These mutant toxins may be used in vaccines for the prevention of bacterial infection. Additionally, dominant negative mutants may be administered as therapeutics for the treatment of bacterial infection.
REFERENCES:
patent: 5591631 (1997-01-01), Leppla et al.
patent: 5677274 (1997-10-01), Leppla et al.
patent: 5792458 (1998-08-01), Johnson et al.
patent: 5917017 (1999-06-01), Collier et al.
patent: 6267966 (2001-07-01), Baillie
patent: 6329156 (2001-12-01), Cirino et al.
patent: 6413768 (2002-07-01), Galen
patent: 6426231 (2002-07-01), Bayley et al.
patent: 6455673 (2002-09-01), Collier et al.
patent: WO 94/18332 (1994-08-01), None
patent: WO 97/23236 (1997-07-01), None
patent: 99/42473 (1999-08-01), None
patent: WO 99/42473 (1999-08-01), None
Bossier, F et al, Infection and Immunity, vol. 68(4), Apr. 2000, pp. 1781-1786.
Moayeri, M et al, Infection and Immunity, vol. 65(6), pp. 2233-2239, Jun. 1997.
Price, Lance B. et al, Journal of Bacteriology, vol. 181(8), pp. 2358-2362, Apr. 1999, Genetic Diversity in the Protective antigen gene ofBacillus anthracis.
Sellmam, BR et al, Journal of Biological Chemistry, vol. 276(11), Mar. 16, 2001, pp. 8371-8376.
Cherry, J.D., Clinical infectious diseases:an official publication of the Infectious Diseases Society of America, Mar. 1999, vol. 28(3), pp. 560-561, (abstract only).
Guttman, Cheryl, Ophthalmology Times, vol. 27, No. 10, p. 17.
Varughese, M et al, Apr. 1999, vol. 67(4), pp. 1860-1865.
Boslego, J. W. et al, Chapter 17, pp. 211-233, Vaccines and Immunotherapies, Pergamon Press, 1991.
Ellis, RW. Chapter 29, New Technologies for Making Vaccines, In : Vaccines, Sunders Company, 1988, pp. 568-574.
Miller, C et al, Protein Science, Voo. 7(1), p. 175, abstract 712-M, 1998.
Miller, CJ et al, Biochemistry, vol. 38, pp. 10432-10441, 1999.
Leppla, SH et al, Journal of Applied Microbiology, vol. 87, p. 284, 1999.
Steinthorsdottir, V et al, Microbial Pathogenesis, Jan. 2000, vol. 28(1), pp. 45-50.
Cabiaux, V et al, Biophys, Journal, Voo. 61 (2 part 2), p. A211, 1992, abstract 1211.
Anderluh, G et al, European Journal of Biochemistry, vol. 263(1), pp. 128-136, Jul. 1999 (germany).
Singh, Y et al, Infection and Immunity, vol. 67(4), pp. 1853-1859, Apr. 1999.
Papageorgiou, AC et al, Protein Science, a publication of the Protein Society, Aug. 1996, Voo. 5(8), pp. 1737-1741.
Tiedemann, RE etal, PNAS, vol. 92(26), pp. 12156-12159, Dec. 19, 1995.
Singh, Y et al, J. Biol. Chem., vol. 269(46), pp. 29039-29046, Nov. 1994.
Yamaoka, J et al, Microbial pathogenesis, Nov. 1997, pp. 297-302, Nov. 1997.
Jobling, MG et al, Mol. Microbiology, vol. 5(7), pp. 1755-1767, 1991.
Singh, Y et al, Journal of Biological Chemistry, vol. 276(25), pp. 22090-22094, Jun. 22, 2001.
Welch, RA, Current Topics in Microbiology and Immunology-Pore-forming toxins, pp. 85-111, vol. 257, 2001.
DeWolf, MJ et al, Biochimica et biophysica acta, Sep. 8, 1994, vol. 1223(3), pp. 285-295.
Anu, D et al, Pesticide Biochemistry and Physiology, May 2001, pp. 7-18, vol. 70(1).
Shatursky, O et al, Cell, Oct. 29, 1999, vol. 99(3), pp. 293-299.
Wesche, J et al, Biochemistry, vol. 37(45) pp. 15737-15746, 1998.
Blaustein, Robert O et al, PNAS (USA), vol. 86, pp. 2209-2213, Apr. 1989.
Kim, Myung-Hee et al, Journal of Biological Chemistry, vol. 275(9), Mar. 3, pp. 6175-6180, 2000.
Sellman, Bret R. et al, The Journal of Biological Chemistry, vol. 276(11), pp. 8371-8376, Mar. 16, 2001.
Sellman, Bret R. et al, Science, vol. 292, Apr. 27, 2001, pp. 695-697.
Wesche, J et al, Biochemistry, vol. 37, pp. 15737-15746, 1998.
Benson et al., “Identification of residues lining the anthrax protective antigen channel,”Biochemistry37:3941-3948 (1998).
Blaustein et al., “Anthrax toxin: channel-forming activity of protective antigen in planar phospholipid bilayers,”Proc. Natl. Acad. Sci. U.S.A.86:2209-2213 (1989).
Braha et al., “Designed protein pores as components for biosensors,”Chemistry&Biology4(7):497-505 (1997).
Elliot et al., “A Quantitative Study of the Interactions ofBacillus anthracisEdema Factor and Lethal Factor with Activated Protective Antigen,”Biochemistry39:6706-6713 (2000).
Huynh et al., “Probing the structure of the diphtheria toxin channel. Reactivity in planar lipid bilayer membranes of cysteine-substituted mutant channels with methanethiosulfonate derivatives,”J. Gen. Physiol.110:229-242 (1997).
Miller et al., “Anthrax Protective Antigen: Prepore-to Pore Conversion,”Biochemistry38(32):10432-10441 (1999).
Miller et al., “Prepore-to Pore Conversion by Activated Anthrax Toxin Protective Antigen,” Protein Science 7(1):175, abstract No. 712-M, (1998).
Milne et al., “Anthrax protective antigen forms oligomers during intoxication of mammalian cells,”J. Biol. Chem.269(32):20607-20612 (1994).
Milne et al., “Protective antigen-binding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino- or carboxy-terminus,”Mol. Microbiol.15(4):661-666 (1995).
Petosa et al., “Crystal structure of the anthrax toxin protective antigen,”Nature385:833-838 (1997).
Sellman et al., “Point Mutations in Anthrax Protective Antigen That Block Translocation,”J. Biol. Chem.276:8371 (2001).
Sellman et al., “Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax,”Science292:695-697 (2001).
Song et al., “Structure ofStaphylococcal α-hemolysin, a heptameric transmembrane pore,”Science274(13):1859-1866 (1996).
Valeva et al., “Transmembrane β-barrel ofStaphylococcalα-toxin forms in sensitive but not in resistant cells,”Proc. Natl. Acad. Sci. U.S.A.94:11607-11611 (1997).
Vinion-Dubiel et al., “A Dominant Negative Mutant ofHeliocobacter pyloriVacuolating Toxin (VacA) Inhibits VacA-induced Cell Vacuolation,” The Journal of Biological Chemistry, 274:37736-37742 (1999).
Vodkin et al., “Cloning of the Protective Antigen Gene ofBacillus anthracis,” Cell34:693-697 (1983).
Walker et al., “A pore-forming protein with a protease-activated trigger,”Protein Engineering7(1):91-97 (1994).
Wesche et al., “Characterization of Membrane Translocation by Anthrax Protective Antigen,”Biochemistry37:15737-15746 (1998).
Klimpel et al., “Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin,”Proc. Natl. Acad. Sci. U.S.A.89:10277-10281 (1992).
Collier R. John
Sellman Bret R.
Clark & Elbing LLP
Portner Ginny Allen
President and Fellows of Harvard College
Smith Lynette R. F.
LandOfFree
Compounds and methods for the treatment and prevention of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for the treatment and prevention of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for the treatment and prevention of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3651862